Media & Press
-
Phebra and University of Wollongong’s promising drug development for leukemias and pancreatic cancer
August 2023
-
Phebra Launches New Australian-Made Sterile Theatre Pack
March 2023
-
Phebra Receives TGA Authorisation for Manufacture of Critical Care Medicines for TGA Trials
March 2022
-
Phebra acquires equity stake in UK Specialty Hospital Pharma company Flexipharm Austrading
November 2021
-
Phebra Plant Expansion Wins NSW Industry Award 2021
September 2021
-
Phebra Announces New Licensing Agreement with Medsenic for the Development of its Oral Arsenic Trioxide Formulation in the Treatment of Chronic Graft-Versus-Host and Autoimmune Diseases
July 2021
-
Final Results of Bioavailability Study of Phebra’s Oral Arsenic Capsule
May 2021
-
Phebra Canada’s Milestones in Delivery of Critical Medicines
April 2021
-
Phebra Secures Supply Of Critical Medicines With Sydney Manufacturing Plant Expansion
December 2020
-
Phebra Signs International Distribution Agreement For Manufacture And Supply Of A New Pharmaceutical For Treatment Of Duchenne Muscular Dystrophy
May 2020